First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
about
First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
First-line therapy with dacomi ...... single-centre, phase 2 study.
@en
First-line therapy with dacomi ...... single-centre, phase 2 study.
@nl
type
label
First-line therapy with dacomi ...... single-centre, phase 2 study.
@en
First-line therapy with dacomi ...... single-centre, phase 2 study.
@nl
prefLabel
First-line therapy with dacomi ...... single-centre, phase 2 study.
@en
First-line therapy with dacomi ...... single-centre, phase 2 study.
@nl
P2093
P2860
P50
P356
P1433
P1476
First-line therapy with dacomi ...... , single-centre, phase 2 study
@en
P2093
Adele Testi
Daniele Raggi
Davide Biasoni
Elena Togliardi
Giuseppina Calareso
Luigi Mariani
Luigi Piva
Mario Catanzaro
Patrizia Giannatempo
Roberto Salvioni
P2860
P304
P356
10.1111/BJU.14013
P577
2017-10-04T00:00:00Z